Neurogene
NGNE
33 hedge funds and large institutions have $39.3M invested in Neurogene in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 5 closing their positions.
0.04% less ownership
Funds ownership: 3.58% → 3.54% (-0.04%)
3% less funds holding
Funds holding: 34 → 33 (-1)
13% less capital invested
Capital invested by funds: $45.5M → $39.3M (-$6.11M)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$259K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$185K |
| 3 |
Squarepoint
New York
|
+$38.5K |
| 4 |
KM
Kalos Management
Alpharetta,
Georgia
|
+$38.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$7.35K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$397K |
| 2 |
JP Morgan Chase
New York
|
-$232K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$103K |
| 4 |
SIM
Spark Investment Management
New York
|
-$101K |
| 5 |
Two Sigma Investments
New York
|
-$76.6K |
NGNE Hedge Fund Activity: Q2 2019 in Review
33 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q2 2019, worth a combined $39.3M — down 13% from $45.5M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of NGNE and 4 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $259K. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $397K sold.
- 33 institutional investors held Neurogene (NGNE) as of Q2 2019, down from 34 in Q1 2019.
- Funds reported $39.3M of Neurogene stock for Q2 2019, down 13% quarter-over-quarter.
- 4 funds opened new Neurogene positions in Q2 2019 and 5 closed out, a net change of -1 holder.
- The largest Neurogene buyer in Q2 2019 was Renaissance Technologies, an estimated $259K added.
- The largest Neurogene seller in Q2 2019 was Highbridge Capital Management, an estimated $397K sold.
Based on aggregated 13F filings for Q2 2019.